BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20662276)

  • 41. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids.
    Nakamura K; Kishimoto T; Ohkawa R; Okubo S; Tozuka M; Yokota H; Ikeda H; Ohshima N; Mizuno K; Yatomi Y
    Anal Biochem; 2007 Aug; 367(1):20-7. PubMed ID: 17568554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Submucosal connective tissue-type mast cells contribute to the production of lysophosphatidic acid (LPA) in the gastrointestinal tract through the secretion of autotaxin (ATX)/lysophospholipase D (lysoPLD).
    Mori K; Kitayama J; Aoki J; Kishi Y; Shida D; Yamashita H; Arai H; Nagawa H
    Virchows Arch; 2007 Jul; 451(1):47-56. PubMed ID: 17554559
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker: study on prostate cancer patients.
    Nakamura K; Takeuchi T; Ohkawa R; Okubo S; Yokota H; Tozuka M; Aoki J; Arai H; Ikeda H; Ohshima N; Kitamura T; Yatomi Y
    Ann Clin Biochem; 2007 Nov; 44(Pt 6):549-56. PubMed ID: 17961310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
    Kishi Y; Okudaira S; Tanaka M; Hama K; Shida D; Kitayama J; Yamori T; Aoki J; Fujimaki T; Arai H
    J Biol Chem; 2006 Jun; 281(25):17492-17500. PubMed ID: 16627485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical introduction of lysophosphatidic acid and autotaxin assays].
    Yatomi Y
    Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Function and biological activities of the autotaxin-LPA axis].
    Li ZW; Zhao YR; Zhao C; Fu R; Li ZY
    Sheng Li Xue Bao; 2011 Dec; 63(6):601-10. PubMed ID: 22193457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases.
    Gendaszewska-Darmach E
    Acta Biochim Pol; 2008; 55(2):227-40. PubMed ID: 18560605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression.
    Panupinthu N; Lee HY; Mills GB
    Br J Cancer; 2010 Mar; 102(6):941-6. PubMed ID: 20234370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulation and biological activities of the autotaxin-LPA axis.
    van Meeteren LA; Moolenaar WH
    Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lysophospholipase D and its role in LPA production.
    Xie Y; Meier KE
    Cell Signal; 2004 Sep; 16(9):975-81. PubMed ID: 15212758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
    Okudaira S; Yukiura H; Aoki J
    Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ATX-LPA receptor axis in inflammation and cancer.
    Liu S; Murph M; Panupinthu N; Mills GB
    Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New insights into the autotaxin/LPA axis in cancer development and metastasis.
    Leblanc R; Peyruchaud O
    Exp Cell Res; 2015 May; 333(2):183-189. PubMed ID: 25460336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Autotaxin and lysophospholipids in rheumatoid arthritis.
    Bourgoin SG; Zhao C
    Curr Opin Investig Drugs; 2010 May; 11(5):515-26. PubMed ID: 20419597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The Laboratory Medicine of Lipid Mediators].
    Yatomi Y
    Rinsho Byori; 2015 Oct; 63(10):1183-6. PubMed ID: 26897854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 3D view of autotaxin.
    Nishimasu H; Ishitani R; Aoki J; Nureki O
    Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mediators of pruritus during cholestasis.
    Oude Elferink RP; Kremer AE; Beuers U
    Curr Opin Gastroenterol; 2011 May; 27(3):289-93. PubMed ID: 21451412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes.
    Sevastou I; Kaffe E; Mouratis MA; Aidinis V
    Biochim Biophys Acta; 2013 Jan; 1831(1):42-60. PubMed ID: 22867755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
    Federico L; Pamuklar Z; Smyth SS; Morris AJ
    Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
    Sun Y; Zhang W; Evans JF; Floreani A; Zou Z; Nishio Y; Qi R; Leung PS; Bowlus CL; Gershwin ME
    Autoimmun Rev; 2016 Aug; 15(8):795-800. PubMed ID: 27019050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.